Hinova Pharmaceuticals, Inc. Class ASSE: 688302

Announcement on Voluntarily Disclosure of Obtaining FDA Approval for Phase I/II Clinical Trial Application of HP537 Tablets in the Treatment of Hematologic Malignancies

· Issued by Hinova Pharmaceuticals, Inc. Class A via Shanghai Stock Exchange
Announcement on Voluntarily Disclosure of Obtaining FDA Approval for Phase I/II Clinical Trial Application of HP537 Tablets in the Treatment of Hematologic Malignancies

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis